No Data
No Data
Blue Sail Medical: 2024 Interim Performance Forecast
Blue Sail Medical (002382.SZ): expected to have a loss of 140-200 million yuan in the first half of the year.
On July 9th, GeLonghui reported that Blue Sail Medical (002382.SZ) announced its performance forecast for the first half of 2024, with a net income loss attributable to the shareholders of the listed company of -0.2 billion yuan to -0.14 billion yuan, an increase of 15.47% to 40.83% compared to the same period last year; the net income loss after deducting the non-recurring gains and losses is -0.23 billion yuan to -0.17 billion yuan, an increase of 27.26% to 46.24% compared to the same period last year; and the basic earnings per share is -0.20 yuan/ share to -0.14 yuan/ share. The protective business unit of the company still showed operating losses in the first half of 2024, but the losses were significantly narrowed compared to the same period last year, and the second
Blue Sail Medical (002382.SZ): The company's private placement of A-share stocks has passed the validity period of the shareholder meeting approval, and will not proceed temporarily.
Blue Sail Medical (002382.SZ) recently stated in a conference call that the private placement of A shares has passed the validity period of the shareholder meeting approval and will not continue for the time being.
Blue Sail Medical (002382.SZ): Currently, the disposable glove industry's production capacity is still in the process of gradual clearance.
Blue Sail Medical (002382.SZ) recently stated in a conference call that the capacity of disposable glove industry is still in the process of gradual clearance. In the past few years, small manufacturers who followed the trend to build factories have closed down due to the lack of operational experience. At present, leading enterprises have the ability and demand to continue to seize market share, and considering the gradual construction of capacity only on the basis of full production and sales of existing capacity, there is significant differentiation among different enterprises.
Blue Sail Medical (002382.SZ): The business of various sectors of the company is currently in a reversal trend, and overall performance, cash flow and other aspects are improving.
Blue Sail Medical (002382.SZ) recently stated in a conference call that the company's balance sheet has sufficient depth and capability. The HKG $20 million capital increase and the previous Blue Sail Bosch $1 billion investment were completed in an extremely cold capital market, essentially reflecting the depth of the company's balance sheet. For example, the company's Shanghai Science and Technology Innovation Center building will soon be put into use and will have a high market fair value in the future. Additionally, Blue Sail Bosch's valuation is also very clear, and many medical instrument companies and institutional investors have discussed with us and highly recognize Blue Sail's value.
Blue Sail Medical (002382.SZ): The company's future capital expenditures will mainly focus on Shandong Health Technology, and may plan industrial layout in countries with better overseas resource endowments.
Blue Sail Medical (002382.SZ) recently stated in a telephone conference that the company's current orders are full, already reaching maximum production and sales, and the production line is running at full capacity. The company's future capital expenditures will mainly focus on Shandong Health Technology, and may expand its industry layout to countries with better overseas resource endowment.
No Data